An Update on Protein Kinases as Therapeutic Targets—Part II: Peptides as Allosteric Protein Kinase C Modulators Targeting Protein–Protein Interactions
Abstract
:1. Protein Kinases
1.1. Protein Kinases as Major Drug Targets
1.2. Noncatalytic Domains of Protein Kinases
1.3. Allosteric Modulation of Kinases
1.4. Use of Allosteric Sites in Drug Discovery
1.5. Allosteric Regulation through Protein–Protein Interactions
2. Peptides Targeting Protein–Protein Interactions
2.1. Therapeutic Application of Peptides
2.2. Approaches to Developed Peptides as Protein Kinase Regulators Targeting Allosteric Sites
3. Peptides Derived from Unique Substrate Sites
3.1. Peptides Derived from the Pseudo-Substrate Site
Peptide | Parent ProteinAA-AA | Protein Accession # | Peptide Sequence | Peptide Role |
---|---|---|---|---|
PKC 19-36 | PKCα/β19-36 | P17252/P05771 | RFARKGALRQKNVHEVKN | Antagonist: the peptide inhibited PKC function [83] |
3.2. Peptides Derived from Substrate Phosphorylation Sites
Peptide | Parent ProteinAA-AA | Protein Accession # | Peptide Sequence | Peptide Role |
---|---|---|---|---|
Nrf2 | Nrf235-44 | Q16236 | VFDFSQRQ | Antagonist: the peptide inhibited PKC function [87]. |
MBP 104-118 | MBP238-252 | P02686 | GKGRGLSLSRPSWGA | Antagonist: the peptide inhibited PKC function [88]. |
HCV (1487-1500) | NS31487-1500 | Q68866 | RRGRTGRGRRGIYR | Antagonist: the peptide inhibited PKC function [91]. |
MZF-1 | MZF-1309-321 | P28698 | SDLRSEQDPTDED | Antagonist: the peptide inhibited PKC expression [93]. |
TMP | Tyrosinase501-511 | P14679 | EDYHSLYQSHL | Antagonist: the peptide inhibited PKC function [95]. |
PSD peptide | MARCKS86-110 | P49006 | KKKKKRFAFKKAFKLAGFAFKKNKK | Antagonist: the peptide inhibited PKC function [96]. |
Octapeptide | EGFR675-682 | P00533 | RKRTLRRL | Antagonist: the peptide inhibited PKC function [103]. |
uPEP2 | uORF21-26 | C0HM02 | MASRGALRRCLSPGLPRLLHLSRGLA | Antagonist: the peptide inhibited PKC function [98]. |
3.3. Peptides Derived from Substrate Protein–Protein Interaction Sites
Peptide | Parent ProteinAA-AA | Protein Accession # | Peptide Sequence | Peptide Role |
---|---|---|---|---|
ψPDK | PKCδ36-40 homolog to PDK391-395 | Q05655 Q15119 | ALSTE ::::. ALSTD | Inhibitor: the peptide inhibited PKCδ binding to PDK [55]. Antagonist: the peptide inhibited PKCδ function [55]. |
ψGAPDH | PKCδ311-316 homolog to GAPDH169-174 | Q05655 P04406 | GIYQGF ::..: GIVEGL | Inhibitor: the peptide inhibited PKCδ binding to GAPDH [114]. Antagonist: the peptide inhibited PKCδ function [114]. |
ψMARCKS | PKCδ75-80 homolog to MARCKS256-261 | Q05655 P29966 | RAAEEP .::::: KAAEEP | Inhibitor: the peptide inhibited PKCδ binding to MARCKS [54]. Antagonist: the peptide inhibited PKCδ function [54]. |
ψDrp1 | PKCδ630-635 homolog to Drp1101-106 | Q05655 O00429 | YSNFDQ :..::. YTDFDE | Inhibitor: the peptide inhibited PKCδ binding to Drp1 [54]. Antagonist: the peptide inhibited PKCδ function [54]. |
ψIRS1 | PKCδ620-626 homolog to IRS1264-270 | Q05655 P35568 | FRPKVKS :::. :: FRPRSKS | Inhibitor: the peptide inhibited PKCδ binding to IRS1 [54]. Antagonist: the peptide inhibited PKCδ function [54]. |
ψTnI | PKCδ54-61 homolog to cTnI190-197 | Q05655 P19429 | EWKSTFDA .:. .:: DWRKNIDA | Inhibitor: the peptide inhibited PKCδ binding to troponin [115]. Antagonist: the peptide inhibited PKCδ function [115]. |
pAnxV | AnnexinV157-164 homolog to PKCδ74-81 | P08758 Q05655 | QANRDP :::::: QANRDP | Inhibitor: the peptide inhibited PKCδ binding to AnnexinV [116]. Antagonist: the peptide inhibited PKCδ translocation and function [116]. |
SAMβA | PKCβII625-629 homolog to Mfn1724-729 | P05771-2 26251799 | N-AENF : ::: NELENF | Inhibitor: the peptide inhibited PKCβII binding to Mfn1 [117]. Antagonist: the peptide inhibited PKCβII translocation and function [117]. |
ψεHSP90 | PKCε139-145 homolog to HSP90α552-558 | Q02156 NP_005339 | PKDNEER :.:.::. PEDEEEK | Activator: the peptide increased PKCε binding to HSP90 [120]. Agonist: the peptide increased PKCε translocation and function [120]. |
4. Peptides Derived from Similar Sequences in Binding Proteins
4.1. Peptides Derived from Sequences Shared by Non-Related Proteins That Interact with a Common Protein
Peptide | Parent ProteinAA-AA | Protein Accession # | Peptide Sequence | Peptide Role |
---|---|---|---|---|
Peptide I | Annexin A1332-346 homolog to 14-3-3122-136 | P04083 P63104 | KGDYEKILVALCGGN ::::.:.:. . : KGDYYRYLAEVAAGD | Inhibitor: the peptide inhibited PKCβ binding to RACK [130]. Antagonist: the peptide inhibited PKCβ translocation and function in vivo [127]. |
RACK1-rIII | RACK1107-113 homolog to 14-3-342-48 | P63244 P04083 | DVLSVAF .::::. NLLSVAY | Inhibitor: the peptide inhibited PKCβ binding to RACK [128]. |
RACK1-rVI | RACK1234-241 homolog to Annexin A1337-344 | P63244 P04083 | DIINALCF .:. ::: KILVALCG | Inhibitor: the peptide inhibited PKCβ binding to RACK [127,128]. Agonist: the peptide induced PKCβ autophosphorylation and substrate phosphorylation [127,128]. |
4.2. Peptides Derived from Sequences Involved in Intramolecular Interactions
5. Evolutionarily Conserved Peptides
5.1. Peptides Derived from Evolutionarily Conserved Sequences
5.2. Peptides Derived from Conserved Sequences in Homologous Domains of Otherwise Non-Related Proteins
Peptide | Parent ProteinAA-AA | Protein Accession # | Peptide Sequence | Peptide Role |
---|---|---|---|---|
βC2-1 | PKCβ209-216 homolog to Synaptotagmin-1193-200 | P05771 P21579 | KQKTKTIK : .:: . KFETKVHR | Inhibitor: the peptide inhibited classic PKCs binding to RACK [142]. Antagonist: the peptide inhibited classic PKC translocation and function [142]. |
βC2-2 | PKCβ186-198 homolog to Synaptotagmin-1174-184 | P05771 P21579 | MDPNGLSDPYVKL : : ::::::. M--GGTSDPYVKV | Inhibitor: the peptide inhibited classic PKCs binding to RACK [142]. Antagonist: the peptide inhibited classic PKC translocation and function [142]. |
βC2-4 | PKCβ218-226 homolog to Synaptotagmin-1202-213 | P05771 P21579 | SLNPEWNET .::: :: TLNPVFNEQ | Inhibitor: the peptide inhibited classic PKCs binding to RACK [142]. Antagonist: the peptide inhibited classic PKC translocation and function [142]. |
CKS-17 | p15E (ENV539-555) homolog to ENV HTL1M376-392 | P03386 P23064 | LQNRRGLDLLFLKEGGL .:::::::::: ..::: AQNRRGLDLLFWEQGGL | Antagonist: the peptide inhibited PKC activity [145] |
6. Peptides Derived from Unique Sequences of the Protein Kinase
6.1. Peptides Derived from Unique Sequences in Homologous Domains of Related Proteins
6.2. Peptides Derived from Sequences That Are Overlapping with Identified Bioactive Peptides in Homologous Domains of Related Proteins
6.3. Peptides Derived from Additional Critical Kinase Domains
7. Summary
Funding
Conflicts of Interest
References
- Carpy, A.; Krug, K.; Graf, S.; Koch, A.; Popic, S.; Hauf, S.; Macek, B. Absolute proteome and phosphoproteome dynamics during the cell cycle of Schizosaccharomyces pombe (Fission Yeast). Mol. Cell Proteom. 2014, 13, 1925–1936. [Google Scholar] [CrossRef]
- Johnson, J.L.; Yaron, T.M.; Huntsman, E.M.; Kerelsky, A.; Song, J.; Regev, A.; Lin, T.Y.; Liberatore, K.; Cizin, D.M.; Cohen, B.M.; et al. An atlas of substrate specificities for the human serine/threonine kinome. Nature 2023, 613, 759–766. [Google Scholar] [CrossRef]
- Kanev, G.K.; de Graaf, C.; de Esch, I.J.P.; Leurs, R.; Würdinger, T.; Westerman, B.A.; Kooistra, A.J. The Landscape of Atypical and Eukaryotic Protein Kinases. Trends Pharmacol. Sci. 2019, 40, 818–832. [Google Scholar] [CrossRef]
- Benn, C.L.; Dawson, L.A. Clinically Precedented Protein Kinases: Rationale for Their Use in Neurodegenerative Disease. Front. Aging Neurosci. 2020, 12, 242. [Google Scholar] [CrossRef]
- Patterson, H.; Nibbs, R.; McInnes, I.; Siebert, S. Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases. Clin. Exp. Immunol. 2014, 176, 1–10. [Google Scholar] [CrossRef]
- Lapenna, S.; Giordano, A. Cell cycle kinases as therapeutic targets for cancer. Nat. Reviews. Drug Discov. 2009, 8, 547–566. [Google Scholar] [CrossRef]
- Newton, A.C.; Brognard, J. Reversing the Paradigm: Protein Kinase C as a Tumor Suppressor. Trends Pharmacol. Sci. 2017, 38, 438–447. [Google Scholar] [CrossRef]
- Rubin, S.J.; Qvit, N. Engineering “Antimicrobial Peptides” and Other Peptides to Modulate Protein-Protein Interactions in Cancer. Curr. Top. Med. Chem. 2020, 20, 2970–2983. [Google Scholar] [CrossRef]
- Amin, F.; Ahmed, A.; Feroz, A.; Khaki, P.S.; Khan, M.S.; Tabrez, S.; Zaidi, S.K.; Abdulaal, W.H.; Shamsi, A.; Khan, W. An update on the association of protein kinases with cardiovascular diseases. Curr. Pharm. Des. 2019, 25, 174–183. [Google Scholar] [CrossRef]
- Fletcher, L. Approval heralds new generation of kinase inhibitors? Nat. Biotechnol. 2001, 19, 599–600. [Google Scholar] [CrossRef]
- Attwood, M.M.; Fabbro, D.; Sokolov, A.V.; Knapp, S.; Schiöth, H.B. Trends in kinase drug discovery: Targets, indications and inhibitor design. Nat. Reviews. Drug Discov. 2021, 20, 839–861. [Google Scholar] [CrossRef]
- Cohen, P.; Cross, D.; Jänne, P.A. Kinase drug discovery 20 years after imatinib: Progress and future directions. Nat. Reviews. Drug Discov. 2021, 20, 551–569. [Google Scholar] [CrossRef]
- de la Torre, B.G.; Albericio, F. The Pharmaceutical Industry in 2021. An Analysis of FDA Drug Approvals from the Perspective of Molecules. Molecules 2022, 27, 1075. [Google Scholar] [CrossRef]
- Smolinski, M.P.; Bu, Y.; Clements, J.; Gelman, I.H.; Hegab, T.; Cutler, D.L.; Fang, J.W.S.; Fetterly, G.; Kwan, R.; Barnett, A.; et al. of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361). J. Med. Chem. 2018, 61, 4704–4719. [Google Scholar] [CrossRef]
- Posas, F.; Saito, H. Osmotic activation of the HOG MAPK pathway via Ste11p MAPKKK: Scaffold role of Pbs2p MAPKK. Science 1997, 276, 1702–1705. [Google Scholar] [CrossRef]
- Mobitz, H.; Jahnke, W.; Cowan-Jacob, S.W. Expanding the Opportunities for Modulating Kinase Targets with Allosteric Approaches. Curr. Top. Med. Chem. 2017, 17, 59–70. [Google Scholar] [CrossRef]
- Wu, P.; Clausen, M.H.; Nielsen, T.E. Allosteric small-molecule kinase inhibitors. Pharmacol. Ther. 2015, 156, 59–68. [Google Scholar] [CrossRef]
- Nussinov, R.; Tsai, C.J.; Csermely, P. Allo-network drugs: Harnessing allostery in cellular networks. Trends Pharmacol. Sci. 2011, 32, 686–693. [Google Scholar] [CrossRef]
- Wang, Z.; Huang, W.; Zhou, K.; Ren, X.; Ding, K. Targeting the Non-Catalytic Functions: A New Paradigm for Kinase Drug Discovery? J. Med. Chem. 2022, 65, 1735–1748. [Google Scholar] [CrossRef]
- Milligan, G.; White, J.H. Protein-protein interactions at G-protein-coupled receptors. Trends Pharmacol. Sci. 2001, 22, 513–518. [Google Scholar] [CrossRef]
- Palmieri, L.; Rastelli, G. αC helix displacement as a general approach for allosteric modulation of protein kinases. Drug Discov. Today 2013, 18, 407–414. [Google Scholar] [CrossRef]
- De Smet, F.; Christopoulos, A.; Carmeliet, P. Allosteric targeting of receptor tyrosine kinases. Nat. Biotechnol. 2014, 32, 1113–1120. [Google Scholar] [CrossRef]
- Fang, Z.; Grutter, C.; Rauh, D. Strategies for the selective regulation of kinases with allosteric modulators: Exploiting exclusive structural features. ACS Chem. Biol. 2013, 8, 58–70. [Google Scholar] [CrossRef]
- Chaikuad, A.; Tacconi, E.M.C.; Zimmer, J.; Liang, Y.; Gray, N.S.; Tarsounas, M.; Knapp, S. A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics. Nat. Chem. Biol. 2014, 10, 853–860. [Google Scholar] [CrossRef]
- Zorba, A.; Nguyen, V.; Koide, A.; Hoemberger, M.; Zheng, Y.; Kutter, S.; Kim, C.; Koide, S.; Kern, D. Allosteric modulation of a human protein kinase with monobodies. Proc. Natl. Acad. Sci. USA 2019, 116, 13937–13942. [Google Scholar] [CrossRef]
- Tovell, H.; Newton, A.C. Protein kinase C showcases allosteric control: Activation of LRRK1. Biochem. J. 2023, 480, 219–223. [Google Scholar] [CrossRef]
- Lian, T.; Li, C.; Wang, H. Trametinib in the treatment of multiple malignancies harboring MEK1 mutations. Cancer Treat. Rev. 2019, 81, 101907. [Google Scholar] [CrossRef]
- Ivanov, A.A.; Khuri, F.R.; Fu, H. Targeting protein-protein interactions as an anticancer strategy. Trends Pharmacol. Sci. 2013, 34, 393–400. [Google Scholar] [CrossRef]
- Khazen, G.; Gyulkhandanian, A.; Issa, T.; Maroun, R.C. Getting to know each other: PPIMem, a novel approach for predicting transmembrane protein-protein complexes. Comput. Struct. Biotechnol. J. 2021, 19, 5184–5197. [Google Scholar] [CrossRef]
- Lu, H.; Zhou, Q.; He, J.; Jiang, Z.; Peng, C.; Tong, R.; Shi, J. Recent advances in the development of protein–protein interactions modulators: Mechanisms and clinical trials. Signal Transduct. Target. Ther. 2020, 5, 213. [Google Scholar] [CrossRef]
- Buyanova, M.; Pei, D. Targeting intracellular protein–protein interactions with macrocyclic peptides. Trends Pharmacol. Sci. 2021, 43, 234–248. [Google Scholar] [CrossRef]
- Arkin, M.R.; Tang, Y.; Wells, J.A. Small-molecule inhibitors of protein-protein interactions: Progressing toward the reality. Chem. Biol. 2014, 21, 1102–1114. [Google Scholar] [CrossRef]
- Jenardhanan, P.; Panneerselvam, M.; Mathur, P.P. Targeting Kinase Interaction Networks: A New Paradigm in PPI Based Design of Kinase Inhibitors. Curr. Top. Med. Chem. 2019, 19, 467–485. [Google Scholar] [CrossRef]
- Rubin, S.; Qvit, N. Cyclic peptides for protein-protein interaction targets: Applications to human disease. Crit. Rev. Eukaryot. Gene Expr. 2016, 26, 199–221. [Google Scholar] [CrossRef]
- Rubin, S.J.; Tal-Gan, Y.; Gilon, C.; Qvit, N. Conversion of protein active regions into peptidomimetic therapeutic leads using backbone cyclization and cycloscan–how to do it yourself! Curr. Top. Med. Chem. 2018, 18, 556–565. [Google Scholar] [CrossRef]
- Rubin, S.J.S.; Qvit, N. Backbone-cyclized peptides: A critical review. Curr. Top. Med. Chem. 2018, 18, 526–555. [Google Scholar] [CrossRef]
- Modell, A.E.; Blosser, S.L.; Arora, P.S. Systematic targeting of protein–protein interactions. Trends Pharmacol. Sci. 2016, 37, 702–713. [Google Scholar] [CrossRef]
- Mannes, M.; Martin, C.; Menet, C.; Ballet, S. Wandering beyond small molecules: Peptides as allosteric protein modulators. Trends Pharmacol. Sci. 2021, 43, 406–423. [Google Scholar] [CrossRef]
- Koshland, D.E. The key-lock theory and the induced fit theory. Angew. Chem. Int. Ed. Engl. 1995, 33, 2375–2378. [Google Scholar] [CrossRef]
- Cunningham, A.D.; Qvit, N.; Mochly-Rosen, D. Peptides and peptidomimetics as regulators of protein-protein interactions. Curr. Opin. Struct. Biol. 2017, 44, 59–66. [Google Scholar] [CrossRef]
- Cabri, W.; Cantelmi, P.; Corbisiero, D.; Fantoni, T.; Ferrazzano, L.; Martelli, G.; Mattellone, A.; Tolomelli, A. Therapeutic Peptides Targeting PPI in Clinical Development: Overview, Mechanism of Action and Perspectives. Front. Mol. Biosci. 2021, 8, 697586. [Google Scholar] [CrossRef]
- Assem, N.; Ferreira, D.J.; Wolan, D.W.; Dawson, P.E. Acetone-linked peptides: A convergent approach for peptide macrocyclization and labeling. Angew. Chem. Int. Ed. Engl. 2015, 54, 8665–8668. [Google Scholar] [CrossRef]
- Gonzalez-Ruiz, D.; Gohlke, H. Targeting protein-protein interactions with small molecules: Challenges and perspectives for computational binding epitope detection and ligand finding. Curr. Med. Chem. 2006, 13, 2607–2625. [Google Scholar] [CrossRef]
- London, N.; Raveh, B.; Schueler-Furman, O. Druggable protein-protein interactions-from hot spots to hot segments. Curr. Opin. Chem. Biol. 2013, 17, 952–959. [Google Scholar] [CrossRef] [PubMed]
- Touti, F.; Gates, Z.P.; Bandyopadhyay, A.; Lautrette, G.; Pentelute, B.L. In-solution enrichment identifies peptide inhibitors of protein–protein interactions. Nat. Chem. Biol. 2019, 15, 410–418. [Google Scholar] [CrossRef]
- Wang, X.; Ni, D.; Liu, Y.; Lu, S. Rational Design of Peptide-Based Inhibitors Disrupting Protein-Protein Interactions. Front. Chem. 2021, 9, 682675. [Google Scholar] [CrossRef] [PubMed]
- Banting, F.G.; Best, C.H.; Collip, J.B.; Campbell, W.R.; Fletcher, A.A. Pancreatic extracts in the treatment of diabetes mellitus. Can. Med. Assoc. J. 1922, 12, 141–146. [Google Scholar] [PubMed]
- de Souza, C.M.; da Silva, Á.P.; Júnior, N.G.O.; Martínez, O.F.; Franco, O.L. Peptides as a therapeutic strategy against Klebsiella pneumoniae. Trends Pharmacol. Sci. 2022, 43, 335–348. [Google Scholar] [CrossRef]
- Muttenthaler, M.; King, G.F.; Adams, D.J.; Alewood, P.F. Trends in peptide drug discovery. Nat. Reviews. Drug Discov. 2021, 20, 309–325. [Google Scholar] [CrossRef]
- Reichert, J. Development trends for peptide therapeutics. In Proceedings of the Peptide Therapeutics Symposium, San Diego, CA, USA, 21–22 October 2010. [Google Scholar]
- Kaspar, A.A.; Reichert, J.M. Future directions for peptide therapeutics development. Drug Discov. Today 2013, 18, 807–817. [Google Scholar] [CrossRef]
- Bhat, A.; Roberts, L.R.; Dwyer, J.J. Lead discovery and optimization strategies for peptide macrocycles. Eur. J. Med. Chem. 2015, 94, 471–479. [Google Scholar] [CrossRef]
- Guidotti, G.; Brambilla, L.; Rossi, D. Cell-penetrating peptides: From basic research to clinics. Trends Pharmacol. Sci. 2017, 38, 406–424. [Google Scholar] [CrossRef] [PubMed]
- Qvit, N.; Kornfeld, O.S.; Mochly-Rosen, D. Engineered substrate-specific delta PKC antagonists to enhance cardiac therapeutics. Angew. Chem. Int. Ed. Engl. 2016, 55, 15672–15679. [Google Scholar] [CrossRef] [PubMed]
- Qvit, N.; Disatnik, M.H.; Sho, J.; Mochly-Rosen, D. Selective phosphorylation inhibitor of delta protein kinase C-pyruvate dehydrogenase kinase protein-protein interactions: Application for myocardial injury in vivo. J. Am. Chem. Soc. 2016, 138, 7626–7635. [Google Scholar] [CrossRef] [PubMed]
- Bates, E.; Bode, C.; Costa, M.; Gibson, C.M.; Granger, C.; Green, C.; Grimes, K.; Harrington, R.; Huber, K.; Kleiman, N.; et al. KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Circulation 2008, 117, 886–896. [Google Scholar] [PubMed]
- Lonn, P.; Dowdy, S.F. Cationic PTD/CPP-mediated macromolecular delivery: Charging into the cell. Expert. Opin. Drug Deliv. 2015, 12, 1627–1636. [Google Scholar] [CrossRef]
- Reichert, J. The Peptide Therapeutics Foundation: Mapping the future of peptide therapeutics. In Proceedings of the Peptide Therapeutics Symposium, La Jolla, CA, USA, 25–26 October 2012. [Google Scholar]
- Fosgerau, K.; Hoffmann, T. Peptide therapeutics: Current status and future directions. Drug Discov. Today 2015, 20, 122–128. [Google Scholar] [CrossRef]
- Qvit, N.; Rubin, S.J.S.; Urban, T.J.; Mochly-Rosen, D.; Gross, E.R. Peptidomimetic therapeutics: Scientific approaches and opportunities. Drug Discov. Today 2017, 22, 454–462. [Google Scholar] [CrossRef] [PubMed]
- Fetse, J.; Kandel, S.; Mamani, U.F.; Cheng, K. Recent advances in the development of therapeutic peptides. Trends Pharmacol. Sci. 2023, 44, 425–441. [Google Scholar] [CrossRef]
- Wexler, I.; Niv, M.; Reuveni, H. Sequence-based protein kinase inhibition: Applications for drug development. Biotechniques 2005, 39 (Suppl. S10), S575–S576. [Google Scholar] [CrossRef]
- Churchill, E.N.; Qvit, N.; Mochly-Rosen, D. Rationally designed peptide regulators of protein kinase C. Trends Endocrinol. Metab. 2009, 20, 25–33. [Google Scholar] [CrossRef]
- Qvit, N. Development and therapeutic applications of oligonucleotides and peptides. Chim. Oggi Chem. Today 2011, 29, 4–7. [Google Scholar]
- Lu, W.; Chen, Q.; Ying, S.; Xia, X.; Yu, Z.; Lui, Y.; Tranter, G.; Jin, B.; Song, C.; Seymour, L.W.; et al. Evolutionarily conserved primary TNF sequences relate to its primitive functions in cell death induction. J. Cell Sci. 2016, 129, 108–120. [Google Scholar] [CrossRef] [PubMed]
- Mochly-Rosen, D.; Qvit, N. Peptide inhibitors of protein-protein interactions. Chim. Oggi Chem. Today 2010, 28, 14–16. [Google Scholar]
- Jia, J.; Jeon, E.J.; Li, M.; Richards, D.J.; Lee, S.; Jung, Y.; Barrs, R.W.; Coyle, R.; Li, X.; Chou, J.C.; et al. Evolutionarily conserved sequence motif analysis guides development of chemically defined hydrogels for therapeutic vascularization. Sci. Adv. 2020, 6, eaaz5894. [Google Scholar] [CrossRef] [PubMed]
- Qvit, N.; Crapster, J.A. Peptides that target protein-protein interactions as an anti-parasite strategy. Chim. Oggi Chem. Today 2014, 32, 62–66. [Google Scholar]
- Qvit, N.; Mochly-Rosen, D. Highly specific modulators of protein kinase C localization: Applications to heart failure. Drug Discov. Today Dis. Mech. 2010, 7, e87–e93. [Google Scholar] [CrossRef] [PubMed]
- Qvit, N.; Mochly-Rosen, D. The many hats of protein kinase C delta: One enzyme with many functions. Biochem. Soc. Trans. 2014, 42, 1529–1533. [Google Scholar] [CrossRef] [PubMed]
- Cunningham, A.D.; Qvit, N. Specific kinase inhibition using peptides to target kinase-substrate docking. Chim. Oggi/Chem. Today 2016, 34, 22–25. [Google Scholar]
- House, C.; Kemp, B.E. Protein kinase C contains a pseudosubstrate prototope in its regulatory domain. Science 1987, 238, 1726–1728. [Google Scholar] [CrossRef]
- Steinberg, S.F. Structural basis of protein kinase C isoform function. Physiol. Rev. 2008, 88, 1341–1378. [Google Scholar] [CrossRef] [PubMed]
- Lee-Kwon, W.; Kim, J.H.; Choi, J.W.; Kawano, K.; Cha, B.; Dartt, D.A.; Zoukhri, D.; Donowitz, M. Ca2+-dependent inhibition of NHE3 requires PKC alpha which binds to E3KARP to decrease surface NHE3 containing plasma membrane complexes. Am. J. Physiology. Cell Physiol. 2003, 285, C1527–C1536. [Google Scholar] [CrossRef] [PubMed]
- Chen, Y.W.; Lang, M.L.; Wade, W.F. Protein kinase C-alpha and -delta are required for FcalphaR (CD89) trafficking to MHC class II compartments and FcalphaR-mediated antigen presentation. Traffic 2004, 5, 577–594. [Google Scholar] [CrossRef] [PubMed]
- Sessoms, J.S.; Chen, S.J.; Chetkovich, D.M.; Powell, C.M.; Roberson, E.D.; Sweatt, J.D.; Klann, E. Ca(2+)-induced persistent protein kinase C activation in rat hippocampal homogenates. Second Messengers Phosphoprot. 1992, 14, 109–126. [Google Scholar]
- Karunakaran, D.; Kockx, M.; Owen, D.M.; Burnett, J.R.; Jessup, W.; Kritharides, L. Protein kinase C controls vesicular transport and secretion of apolipoprotein E from primary human macrophages. J. Biol. Chem. 2013, 288, 5186–5197. [Google Scholar] [CrossRef]
- Leonard, T.A.; Rozycki, B.; Saidi, L.F.; Hummer, G.; Hurley, J.H. Crystal structure and allosteric activation of protein kinase C betaII. Cell 2011, 144, 55–66. [Google Scholar] [CrossRef]
- Souroujon, M.C.; Mochly-Rosen, D. Peptide modulators of protein-protein interactions in intracellular signaling. Nat. Biotechnol. 1998, 16, 919–924. [Google Scholar] [CrossRef]
- Kheifets, V.; Mochly-Rosen, D. Insight into intra- and inter-molecular interactions of PKC: Design of specific modulators of kinase function. Pharmacol. Res. 2007, 55, 467–476. [Google Scholar] [CrossRef]
- Stahelin, R.V.; Wang, J.; Blatner, N.R.; Rafter, J.D.; Murray, D.; Cho, W. The origin of C1A-C2 interdomain interactions in protein kinase Calpha. J. Biol. Chem. 2005, 280, 36452–36463. [Google Scholar] [CrossRef]
- Chen, D.; Purohit, A.; Halilovic, E.; Doxsey, S.J.; Newton, A.C. Centrosomal anchoring of protein kinase C betaII by pericentrin controls microtubule organization, spindle function, and cytokinesis. J. Biol. Chem. 2004, 279, 4829–4839. [Google Scholar] [CrossRef]
- House, C.; Kemp, B.E. Protein kinase C pseudosubstrate prototope: Structure-function relationships. Cell. Signal. 1990, 2, 187–190. [Google Scholar] [CrossRef] [PubMed]
- Holub, J.M. Novel Peptide-Based Inhibitors of Protein Kinases. In Next Generation Kinase Inhibitors; Springer: Berlin/Heidelberg, Germany, 2020; pp. 169–206. [Google Scholar]
- Schrödinger, L.; DeLano, W. PyMOL, 2020. Available online: http://www.pymol.org/pymol (accessed on 1 October 2023).
- Zhou, P.; Jin, B.; Li, H.; Huang, S.Y. HPEPDOCK: A web server for blind peptide-protein docking based on a hierarchical algorithm. Nucleic Acids Res. 2018, 46, W443–W450. [Google Scholar] [CrossRef] [PubMed]
- Huang, H.C.; Nguyen, T.; Pickett, C.B. Phosphorylation of Nrf2 at Ser-40 by protein kinase C regulates antioxidant response element-mediated transcription. J. Biol. Chem. 2002, 277, 42769–42774. [Google Scholar] [CrossRef] [PubMed]
- Su, H.D.; Kemp, B.E.; Turner, R.S.; Kuo, J.F. Synthetic myelin basic protein peptide analogs are specific inhibitors of phospholipid/calcium-dependent protein kinase (protein kinase C). Biochem. Biophys. Res. Commun. 1986, 134, 78–84. [Google Scholar] [CrossRef] [PubMed]
- Vartanian, T.; Dawson, G.; Soliven, B.; Nelson, D.J.; Szuchet, S. Phosphorylation of myelin basic protein in intact oligodendrocytes: Inhibition by galactosylsphingosine and cyclic AMP. Glia 1989, 2, 370–379. [Google Scholar] [CrossRef] [PubMed]
- Borowski, P.; Oehlmann, K.; Heiland, M.; Laufs, R. Nonstructural protein 3 of hepatitis C virus blocks the distribution of the free catalytic subunit of cyclic AMP-dependent protein kinase. J. Virol. 1997, 71, 2838–2843. [Google Scholar] [CrossRef]
- Borowski, P.; Schulze zur Wiesch, J.; Resch, K.; Feucht, H.; Laufs, R.; Schmitz, H. Protein kinase C recognizes the protein kinase A-binding motif of nonstructural protein 3 of hepatitis C virus. J. Biol. Chem. 1999, 274, 30722–30728. [Google Scholar] [CrossRef]
- Hsieh, Y.H.; Wu, T.T.; Tsai, J.H.; Huang, C.Y.; Hsieh, Y.S.; Liu, J.Y. PKCalpha expression regulated by Elk-1 and MZF-1 in human HCC cells. Biochem. Biophys. Res. Commun. 2006, 339, 217–225. [Google Scholar] [CrossRef]
- Yue, C.H.; Liu, L.C.; Kao, E.S.; Lin, H.; Hsu, L.S.; Hsu, C.W.; Lin, Y.Y.; Lin, Y.S.; Liu, J.Y.; Lee, C.J. Protein kinase C α is involved in the regulation of AXL receptor tyrosine kinase expression in triple-negative breast cancer cells. Mol. Med. Rep. 2016, 14, 1636–1642. [Google Scholar] [CrossRef]
- Park, H.Y.; Perez, J.M.; Laursen, R.; Hara, M.; Gilchrest, B.A. Protein kinase C-beta activates tyrosinase by phosphorylating serine residues in its cytoplasmic domain. J. Biol. Chem. 1999, 274, 16470–16478. [Google Scholar] [CrossRef]
- Park, H.Y.; Lee, J.; González, S.; Middelkamp-Hup, M.A.; Kapasi, S.; Peterson, S.; Gilchrest, B.A. Topical application of a protein kinase C inhibitor reduces skin and hair pigmentation. J. Investig. Dermatol. 2004, 122, 159–166. [Google Scholar] [CrossRef]
- Graff, J.M.; Rajan, R.R.; Randall, R.R.; Nairn, A.C.; Blackshear, P.J. Protein kinase C substrate and inhibitor characteristics of peptides derived from the myristoylated alanine-rich C kinase substrate (MARCKS) protein phosphorylation site domain. J. Biol. Chem. 1991, 266, 14390–14398. [Google Scholar] [CrossRef] [PubMed]
- Song, J.C.; Hrnjez, B.J.; Farokhzad, O.C.; Matthews, J.B. PKC-epsilon regulates basolateral endocytosis in human T84 intestinal epithelia: Role of F-actin and MARCKS. Am. J. Physiol. 1999, 277, C1239–C1249. [Google Scholar] [CrossRef] [PubMed]
- Jayaram, D.R.; Frost, S.; Argov, C.; Liju, V.B.; Anto, N.P.; Muraleedharan, A.; Ben-Ari, A.; Sinay, R.; Smoly, I.; Novoplansky, O.; et al. Unraveling the hidden role of a uORF-encoded peptide as a kinase inhibitor of PKCs. Proc. Natl. Acad. Sci. USA 2021, 118, e2018899118. [Google Scholar] [CrossRef]
- Hunter, T.; Ling, N.; Cooper, J.A. Protein kinase C phosphorylation of the EGF receptor at a threonine residue close to the cytoplasmic face of the plasma membrane. Nature 1984, 311, 480–483. [Google Scholar] [CrossRef] [PubMed]
- Ward, N.E.; Gravitt, K.R.; O’Brian, C.A. Irreversible inactivation of protein kinase C by a peptide-substrate analog. J. Biol. Chem. 1995, 270, 8056–8060. [Google Scholar] [CrossRef]
- de Bont, H.B.; Liskamp, R.M.; O’Brian, C.A.; Erkelens, C.; Veeneman, G.H.; van Boom, J.H. Synthesis of a substrate of protein kinase C and its corresponding phosphopeptide. Int. J. Pept. Protein Res. 1989, 33, 115–123. [Google Scholar] [CrossRef]
- O’Brian, C.A.; Ward, N.E.; Liskamp, R.M.; de Bont, D.B.; van Boom, J.H. N-myristyl-Lys-Arg-Thr-Leu-Arg: A novel protein kinase C inhibitor. Biochem. Pharmacol. 1990, 39, 49–57. [Google Scholar] [CrossRef] [PubMed]
- Heasley, L.E.; Johnson, G.L. Regulation of protein kinase C by nerve growth factor, epidermal growth factor, and phorbol esters in PC12 pheochromocytoma cells. J. Biol. Chem. 1989, 264, 8646–8652. [Google Scholar] [CrossRef]
- Ubersax, J.A.; Ferrell, J.E., Jr. Mechanisms of specificity in protein phosphorylation. Nat. Rev. Mol. Cell Biol. 2007, 8, 530–541. [Google Scholar] [CrossRef]
- Sharrocks, A.D.; Yang, S.H.; Galanis, A. Docking domains and substrate-specificity determination for MAP kinases. Trends Biochem. Sci. 2000, 25, 448–453. [Google Scholar] [CrossRef] [PubMed]
- Bardwell, L.; Cook, J.G.; Chang, E.C.; Cairns, B.R.; Thorner, J. Signaling in the yeast pheromone response pathway: Specific and high-affinity interaction of the mitogen-activated protein (MAP) kinases Kss1 and Fus3 with the upstream MAP kinase kinase Ste7. Mol. Cell. Biol. 1996, 16, 3637–3650. [Google Scholar] [CrossRef] [PubMed]
- Bardwell, L.; Thorner, J. A conserved motif at the amino termini of MEKs might mediate high-affinity interaction with the cognate MAPKs. Trends Biochem. Sci. 1996, 21, 373–374. [Google Scholar] [CrossRef] [PubMed]
- Williams, D.D.; Marin, O.; Pinna, L.A.; Proud, C.G. Phosphorylated seryl and threonyl, but not tyrosyl, residues are efficient specificity determinants for GSK-3β and Shaggy. FEBS Lett. 1999, 448, 86–90. [Google Scholar] [CrossRef]
- Biondi, R.M.; Cheung, P.C.; Casamayor, A.; Deak, M.; Currie, R.A.; Alessi, D.R. Identification of a pocket in the PDK1 kinase domain that interacts with PIF and the C-terminal residues of PKA. EMBO J. 2000, 19, 979–988. [Google Scholar] [CrossRef]
- Adams, P.D.; Sellers, W.R.; Sharma, S.K.; Wu, A.D.; Nalin, C.M.; Kaelin, W.G., Jr. Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors. Mol. Cell. Biol. 1996, 16, 6623–6633. [Google Scholar] [CrossRef]
- Schulman, B.A.; Lindstrom, D.L.; Harlow, E. Substrate recruitment to cyclin-dependent kinase 2 by a multipurpose docking site on cyclin A. Proc. Natl. Acad. Sci. USA 1998, 95, 10453–10458. [Google Scholar] [CrossRef]
- Tokunaga, Y.; Takeuchi, K.; Takahashi, H.; Shimada, I. Allosteric enhancement of MAP kinase p38alpha’s activity and substrate selectivity by docking interactions. Nat. Struct. Mol. Biol. 2014, 21, 704–711. [Google Scholar] [CrossRef]
- Alexa, A.; Ember, O.; Szabó, I.; Mo’ath, Y.; Póti, Á.L.; Reményi, A.; Bánóczi, Z. Peptide Based Inhibitors of Protein Binding to the Mitogen-Activated Protein Kinase Docking Groove. Front. Mol. Biosci. 2021, 8, 690429. [Google Scholar] [CrossRef]
- Qvit, N.; Joshi, A.U.; Cunningham, A.D.; Ferreira, J.C.; Mochly-Rosen, D. GAPDH (glyceraldehyde-3-phosphate dehydrogenase) protein-protein interaction inhibitor reveals a non-catalytic role for GAPDH oligomerization in cell death. J. Biol. Chem. 2016, 291, 13608–13621. [Google Scholar] [CrossRef]
- Qvit, N.; Lin, A.J.; Elezaby, A.; Ostberg, N.P.; Campos, J.C.; Ferreira, J.C.B.; Mochly-Rosen, D. A Selective Inhibitor of Cardiac Troponin I Phosphorylation by Delta Protein Kinase C (δPKC) as a Treatment for Ischemia-Reperfusion Injury. Pharmaceuticals 2022, 15, 271. [Google Scholar] [CrossRef] [PubMed]
- Kheifets, V.; Bright, R.; Inagaki, K.; Schechtman, D.; Mochly-Rosen, D. Protein kinase C delta (deltaPKC)-annexin V interaction: A required step in deltaPKC translocation and function. J. Biol. Chem. 2006, 281, 23218–23226. [Google Scholar] [CrossRef] [PubMed]
- Ferreira, J.C.B.; Campos, J.C.; Qvit, N.; Qi, X.; Bozi, L.H.M.; Bechara, L.R.G.; Lima, V.M.; Queliconi, B.B.; Disatnik, M.H.; Dourado, P.M.M.; et al. A selective inhibitor of mitofusin 1-betaIIPKC association improves heart failure outcome in rats. Nat. Commun. 2019, 10, 329. [Google Scholar] [CrossRef] [PubMed]
- Cao, Y.L.; Meng, S.; Chen, Y.; Feng, J.X.; Gu, D.D.; Yu, B.; Li, Y.J.; Yang, J.Y.; Liao, S.; Chan, D.C.; et al. MFN1 structures reveal nucleotide-triggered dimerization critical for mitochondrial fusion. Nature 2017, 542, 372–376. [Google Scholar] [CrossRef] [PubMed]
- Chen, L.; Hahn, H.; Wu, G.; Chen, C.H.; Liron, T.; Schechtman, D.; Cavallaro, G.; Banci, L.; Guo, Y.; Bolli, R.; et al. Opposing cardioprotective actions and parallel hypertrophic effects of delta PKC and epsilon PKC. Proc. Natl. Acad. Sci. USA 2001, 98, 11114–11119. [Google Scholar] [CrossRef]
- Budas, G.R.; Churchill, E.N.; Disatnik, M.H.; Sun, L.; Mochly-Rosen, D. Mitochondrial import of PKCe is mediated by HSP90: A role in cardioprotection from ischemia and reperfusion injury. Cardiovasc. Res. 2010, 88, 83–92. [Google Scholar] [CrossRef]
- Pawson, T.; Scott, J.D. Signaling through scaffold, anchoring, and adaptor proteins. Science 1997, 278, 2075–2080. [Google Scholar] [CrossRef]
- Carr, D.W.; Hausken, Z.E.; Fraser, I.D.; Stofko-Hahn, R.E.; Scott, J.D. Association of the type II cAMP-dependent protein kinase with a human thyroid RII-anchoring protein. Cloning and characterization of the RII-binding domain. J. Biol. Chem. 1992, 267, 13376–13382. [Google Scholar] [CrossRef]
- Dintilhac, A.; Bernués, J. HMGB1 interacts with many apparently unrelated proteins by recognizing short amino acid sequences. J. Biol. Chem. 2002, 277, 7021–7028. [Google Scholar] [CrossRef]
- Hakes, L.; Lovell, S.C.; Oliver, S.G.; Robertson, D.L. Specificity in protein interactions and its relationship with sequence diversity and coevolution. Proc. Natl. Acad. Sci. USA 2007, 104, 7999–8004. [Google Scholar] [CrossRef]
- Aitken, A.; Ellis, C.A.; Harris, A.; Sellers, L.A.; Toker, A. Kinase and neurotransmitters. Nature 1990, 344, 594. [Google Scholar] [CrossRef] [PubMed]
- Mochly-Rosen, D.; Khaner, H.; Lopez, J. Identification of intracellular receptor proteins for activated protein kinase C. Proc. Natl. Acad. Sci. USA 1991, 88, 3997–4000. [Google Scholar] [CrossRef] [PubMed]
- Ron, D.; Mochly-Rosen, D. Agonists and antagonists of protein kinase C function, derived from its binding proteins. J. Biol. Chem. 1994, 269, 21395–21398. [Google Scholar] [CrossRef] [PubMed]
- Ron, D.; Chen, C.H.; Caldwell, J.; Jamieson, L.; Orr, E.; Mochly-Rosen, D. Cloning of an intracellular receptor for protein kinase C: A homolog of the beta subunit of G proteins. Proc. Natl. Acad. Sci. USA 1994, 91, 839–843. [Google Scholar] [CrossRef] [PubMed]
- Nguyen, T.A.; Takemoto, L.J.; Takemoto, D.J. Inhibition of gap junction activity through the release of the C1B domain of protein kinase Cgamma (PKCgamma) from 14-3-3: Identification of PKCgamma-binding sites. J. Biol. Chem. 2004, 279, 52714–52725. [Google Scholar] [CrossRef] [PubMed]
- Mochly-Rosen, D.; Khaner, H.; Lopez, J.; Smith, B.L. Intracellular receptors for activated protein kinase C. Identification of a binding site for the enzyme. J. Biol. Chem. 1991, 266, 14866–14868. [Google Scholar] [CrossRef] [PubMed]
- Ron, D.; Mochly-Rosen, D. An Autoregulatory Region in Protein-Kinase-C—The Pseudoanchoring Site. Proc. Natl. Acad. Sci. USA 1995, 92, 492–496. [Google Scholar] [CrossRef]
- Dorn, G.W.; Souroujon, M.C.; Liron, T.; Chen, C.H.; Gray, M.O.; Zhou, H.Z.; Csukai, M.; Wu, G.; Lorenz, J.N.; Mochly-Rosen, D. Sustained in vivo cardiac protection by a rationally designed peptide that causes epsilon protein kinase C translocation. Proc. Natl. Acad. Sci. USA 1999, 96, 12798–12803. [Google Scholar] [CrossRef]
- Liron, T.; Chen, L.E.; Khaner, H.; Vallentin, A.; Mochly-Rosen, D. Rational design of a selective antagonist of epsilon protein kinase C derived from the selective allosteric agonist, pseudo-RACK peptide. J. Mol. Cell. Cardiol. 2007, 42, 835–841. [Google Scholar] [CrossRef]
- Johnson, J.A.; Gray, M.O.; Chen, C.H.; Mochly-Rosen, D. A protein kinase C translocation inhibitor as an isozyme-selective antagonist of cardiac function. J. Biol. Chem. 1996, 271, 24962–24966. [Google Scholar] [CrossRef]
- Lichtarge, O.; Bourne, H.R.; Cohen, F.E. An evolutionary trace method defines binding surfaces common to protein families. J. Mol. Biol. 1996, 257, 342–358. [Google Scholar] [CrossRef]
- Mihalek, I.; Reš, I.; Lichtarge, O. A family of evolution–entropy hybrid methods for ranking protein residues by importance. J. Mol. Biol. 2004, 336, 1265–1282. [Google Scholar] [CrossRef]
- Huang, Y.W.; Chang, C.M.; Lee, C.W.; Hwang, J.K. The conservation profile of a protein bears the imprint of the molecule that is evolutionarily coupled to the protein. Proteins: Struct. Funct. Bioinform. 2015, 83, 1407–1413. [Google Scholar] [CrossRef]
- Gray, M.O.; Karliner, J.S.; Mochly-Rosen, D. A selective epsilon-protein kinase C antagonist inhibits protection of cardiac myocytes from hypoxia-induced cell death. J. Biol. Chem. 1997, 272, 30945–30951. [Google Scholar] [CrossRef] [PubMed]
- Chandrashekaran, I.R.; Norton, R.S.; Schmitz-Peiffer, C. Characterisation of peptide interactions that regulate PKCε activation. FEBS Lett. 2018, 592, 179–189. [Google Scholar] [CrossRef] [PubMed]
- Clark, J.D.; Lin, L.L.; Kriz, R.W.; Ramesha, C.S.; Sultzman, L.A.; Lin, A.Y.; Milona, N.; Knopf, J.L. A novel arachidonic acid-selective cytosolic PLA2 contains a Ca(2+)-dependent translocation domain with homology to PKC and GAP. Cell 1991, 65, 1043–1051. [Google Scholar] [CrossRef] [PubMed]
- Mochly-Rosen, D.; Miller, K.G.; Scheller, R.H.; Khaner, H.; Lopez, J.; Smith, B.L. p65 fragments, homologous to the C2 region of protein kinase C, bind to the intracellular receptors for protein kinase C. Biochemistry 1992, 31, 8120–8124. [Google Scholar] [CrossRef] [PubMed]
- Ron, D.; Luo, J.; Mochly-Rosen, D. C2 region-derived peptides inhibit translocation and function of beta protein kinase C in vivo. J. Biol. Chem. 1995, 270, 24180–24187. [Google Scholar] [CrossRef] [PubMed]
- Cianciolo, G.J.; Copeland, T.D.; Oroszlan, S.; Snyderman, R. Inhibition of lymphocyte proliferation by a synthetic peptide homologous to retroviral envelope proteins. Science 1985, 230, 453–455. [Google Scholar] [CrossRef] [PubMed]
- Cianciolo, G.J.; Kipnis, R.J.; Snyderman, R. Similarity between p15E of murine and feline leukaemia viruses and p21 of HTLV. Nature 1984, 311, 515. [Google Scholar] [CrossRef]
- Gottlieb, R.A.; Kleinerman, E.S.; O’Brian, C.A.; Tsujimoto, S.; Cianciolo, G.J.; Lennarz, W.J. Inhibition of protein kinase C by a peptide conjugate homologous to a domain of the retroviral protein p15E. J. Immunol. 1990, 145, 2566–2570. [Google Scholar] [CrossRef] [PubMed]
- Stebbins, E.G.; Mochly-Rosen, D. Binding specificity for RACK1 resides in the v5 region of beta II protein kinase C. J. Biol. Chem. 2001, 276, 29644–29650. [Google Scholar] [CrossRef] [PubMed]
- Sweitzer, S.M.; Wong, S.M.; Tjolsen, A.; Allen, C.P.; Mochly-Rosen, D.; Kendig, J.J. Exaggerated nociceptive responses on morphine withdrawal: Roles of protein kinase C epsilon and gamma. Pain 2004, 110, 281–289. [Google Scholar] [CrossRef] [PubMed]
- Sweitzer, S.M.; Wong, S.M.; Peters, M.C.; Mochly-Rosen, D.; Yeomans, D.C.; Kendig, J.J. Protein kinase C epsilon and gamma: Involvement in formalin-induced nociception in neonatal rats. J. Pharmacol. Exp. Ther. 2004, 309, 616–625. [Google Scholar] [CrossRef]
- Shumilla, J.A.; Liron, T.; Mochly-Rosen, D.; Kendig, J.J.; Sweitzer, S.M. Ethanol withdrawal-associated allodynia and hyperalgesia: Age-dependent regulation by protein kinase C epsilon and gamma isoenzymes. J. Pain 2005, 6, 535–549. [Google Scholar] [CrossRef]
- Kim, J.; Thorne, S.H.; Sun, L.; Huang, B.; Mochly-Rosen, D. Sustained inhibition of PKCalpha reduces intravasation and lung seeding during mammary tumor metastasis in an in vivo mouse model. Oncogene 2011, 30, 323–333. [Google Scholar] [CrossRef]
- Gökmen-Polar, Y.; Fields, A.P. Mapping of a molecular determinant for protein kinase C betaII isozyme function. J. Biol. Chem. 1998, 273, 20261–20266. [Google Scholar] [CrossRef]
- Todt, J.C.; Hu, B.; Punturieri, A.; Sonstein, J.; Polak, T.; Curtis, J.L. Activation of protein kinase C beta II by the stereo-specific phosphatidylserine receptor is required for phagocytosis of apoptotic thymocytes by resident murine tissue macrophages. J. Biol. Chem. 2002, 277, 35906–35914. [Google Scholar] [CrossRef]
- Pappa, H.; Murray-Rust, J.; Dekker, L.V.; Parker, P.J.; McDonald, N.Q. Crystal structure of the C2 domain from protein kinase C-delta. Structure 1998, 6, 885–894. [Google Scholar] [CrossRef] [PubMed]
- Miyaji, Y.; Walter, S.; Chen, L.; Kurihara, A.; Ishizuka, T.; Saito, M.; Kawai, K.; Okazaki, O. Distribution of KAI-9803, a Novel (delta)-Protein Kinase C Inhibitor, after Intravenous Administration to Rats. Drug Metab. Dispos. Biol. Fate Chem. 2011, 39, 1946–1953. [Google Scholar] [CrossRef] [PubMed]
- Xiao, G.Q.; Mochly-Rosen, D.; Boutjdir, M. PKC isozyme selective regulation of cloned human cardiac delayed slow rectifier K current. Biochem. Biophys. Res. Commun. 2003, 306, 1019–1025. [Google Scholar] [CrossRef] [PubMed]
- Liu, G.S.; Cohen, M.V.; Mochly-Rosen, D.; Downey, J.M. Protein kinase C-epsilon is responsible for the protection of preconditioning in rabbit cardiomyocytes. J. Mol. Cell. Cardiol. 1999, 31, 1937–1948. [Google Scholar] [CrossRef] [PubMed]
- Kanthasamy, A.G.; Anantharam, V.; Zhang, D.; Latchoumycandane, C.; Jin, H.; Kaul, S.; Kanthasamy, A. A novel peptide inhibitor targeted to caspase-3 cleavage site of a proapoptotic kinase protein kinase C delta (PKCδ) protects against dopaminergic neuronal degeneration in Parkinson’s disease models. Free Radic. Biol. Med. 2006, 41, 1578–1589. [Google Scholar] [CrossRef] [PubMed]
- Kosugi, S.; Hasebe, M.; Entani, T.; Takayama, S.; Tomita, M.; Yanagawa, H. Design of peptide inhibitors for the importin alpha/beta nuclear import pathway by activity-based profiling. Chem. Biol. 2008, 15, 940–949. [Google Scholar] [CrossRef]
- Dunn, J.; McCuaig, R.D.; Tan, A.H.Y.; Tu, W.J.; Wu, F.; Wagstaff, K.M.; Zafar, A.; Ali, S.; Diwakar, H.; Dahlstrom, J.E.; et al. Selective Targeting of Protein Kinase C (PKC)-θ Nuclear Translocation Reduces Mesenchymal Gene Signatures and Reinvigorates Dysfunctional CD8(+) T Cells in Immunotherapy-Resistant and Metastatic Cancers. Cancers 2022, 14, 1596. [Google Scholar] [CrossRef]
- Goebel, G.L.; Qiu, X.; Wu, P. Kinase-targeting small-molecule inhibitors and emerging bifunctional molecules. Trends Pharmacol. Sci. 2022, 43, 866–881. [Google Scholar] [CrossRef]
Peptide | Parent ProteinAA-AA | Protein Accession # | Peptide Sequence | Peptide Role |
---|---|---|---|---|
ψRACK1 (ψβRACK) | PKCβ241-246 homolog to RACK1255-260 | P05771 P63244 | SVEIWD :..::: SIKIWD | Inhibitor: the peptide inhibited PKCβ binding to RACK [131]. Agonist: the peptide activates PKCβ in the absence of PKC activators [131]. |
ψεRACK (εV1-7) | PKCε85–92 homolog to β′-COP285-292 | Q02156 P35606 | HDAPIGYD . .::: NNVALGYD | Agonist: the peptide increased PKCε translocation and function [132]. |
ψδRACK | PKCδ71-83 (74-81 underlined) homolog to Annexin V154-166 | Q05655 P08758 | IVLMRRAEDPMSE .:: .: .:: VVLLQANRDPDAG | Agonist: the peptide increased PKCδ translocation and function [119]. |
Peptide | Parent ProteinAA-AA | Protein Accession # | Peptide Sequence | Peptide Role |
---|---|---|---|---|
εV1-2 | PKCε14-21 (human) homolog to PKCε19-26 (slug) | Q02156 Q16975 | EAVSLKPT ::: :::: EAVDLKPT | Inhibitor: the peptide inhibited PKCε binding to RACK [139]. Antagonist: the peptide inhibited PKCε translocation and function [134]. |
ψεRACK (εV1-7) | PKCε85-92 homolog to PKCε84-91 (Slug) | Q02156 Q16975 | HDAPIGYD ::: : : HDAAIPPD | Agonist: the peptide increased PKCε translocation and function [132]. |
Peptide | Parent ProteinAA-AA | Protein Accession # | Peptide Sequence | Peptide Role |
---|---|---|---|---|
βIV5-3 | PKCβI646-651 least similar to PKCβII645-650 | P05771-1 P05771-2 | KLFIMN . : QEVIRN | Antagonist: the peptide inhibited PKCβI translocation and function [146]. |
βIIV5-1 | PKCβII660-673 least similar to PKCβI661-671 | P05771-2 P05771-1 | SFVNSEFLKPEVKS :. : ::. SYTNPEFVINV--- | Inhibitor: the peptide partially inhibited PKCβII binding to RACK [146]. Antagonist: the peptide inhibited PKCβII function [151,152]. |
βIIV5-2 | PKCβII621-627 least similar to PKCβI621-627 | P05771-2 P05771-1 | ACGRNAE : . ARDKRDT | Inhibitor: the peptide partially inhibited PKCβII binding to RACK [146]. |
βIIV5-3 | PKCβII645-650 least similar to PKCβI646-651 | P05771-2 P05771-1 | QEVIRN . : KLFIMN | Inhibitor: the peptide partially inhibited PKCβII binding to RACK [146]. Antagonist: the peptide inhibited PKCβII translocation and function [146]. |
γV5-3 | PKCγ659-664 least similar to PKCβII645-650 | P05129 P05771-2 | RLVLAS . :. QEVIRN | Antagonist: the peptide inhibited PKCγ translocation and function [147,148,149]. |
αV5-3 | PKCα642-647 least similar to PKCβII645-650 | P17252 P05771-2 | QLVIAN : :: : QEVIRN | Antagonist: the peptide inhibited PKCγ translocation and function [150]. |
Peptide | Parent ProteinAA-AA | Protein Accession # | Peptide Sequence | Peptide Role |
---|---|---|---|---|
δV1-1 (KAI-9803) | PKCδ8–17 | Q05655 | SFNSYELGSL | Antagonist: the peptide inhibited PKCδ translocation and function [119]. |
ηV1-2 | PKCη18-25 | P24723 | EAVGLQPT | Antagonist: the peptide inhibited PKCη translocation and function [156]. |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Zerihun, M.; Rubin, S.J.S.; Silnitsky, S.; Qvit, N. An Update on Protein Kinases as Therapeutic Targets—Part II: Peptides as Allosteric Protein Kinase C Modulators Targeting Protein–Protein Interactions. Int. J. Mol. Sci. 2023, 24, 17504. https://doi.org/10.3390/ijms242417504
Zerihun M, Rubin SJS, Silnitsky S, Qvit N. An Update on Protein Kinases as Therapeutic Targets—Part II: Peptides as Allosteric Protein Kinase C Modulators Targeting Protein–Protein Interactions. International Journal of Molecular Sciences. 2023; 24(24):17504. https://doi.org/10.3390/ijms242417504
Chicago/Turabian StyleZerihun, Mulate, Samuel J. S. Rubin, Shmuel Silnitsky, and Nir Qvit. 2023. "An Update on Protein Kinases as Therapeutic Targets—Part II: Peptides as Allosteric Protein Kinase C Modulators Targeting Protein–Protein Interactions" International Journal of Molecular Sciences 24, no. 24: 17504. https://doi.org/10.3390/ijms242417504